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Background. Recent studies suggested that non-protein-coding genes are implicated in the tumorigenic process of nasopharyngeal
carcinoma (NPC). In the present study, we aimed to identify the differentially expressed long noncoding RNA (lncRNA) using data
available in the public domain.Methods. Microarray data set GSE12452 was reannotated with ncFANs. Real-time quantitative PCR
was used to quantify and validate the identified lncRNAs in NPC. Results. In primary NPC, upregulation of lnc-C22orf32-1, lnc-
AL355149.1-1, and lnc-ZNF674-1 was observed. High levels of lnc-C22orf32-1 and lnc-AL355149.1-1 were significantly associatedwith
themale patients. In addition, increased expression of lnc-C22orf32-1 and lnc-ZNF674-1was associatedwith advanced tumor stages.
Recurrent NPC displayed a distinctive lncRNA expression pattern. lnc-BCL2L11-3 was significantly increased in the recurrent
NPC tissues. In addition, significant reduction of lnc-AL355149.1-1 and lnc-ZNF674-1 was observed in the recurrent NPC tissues.
Conclusions. Our results demonstrated that it is feasible to identify the differentially expressed lncRNA in the microarray dataset by
functional reannotation.The association of lncRNAwith gender and tumor size implicated that lncRNA possibly plays a part in the
pathogenesis of primaryNPC. Further, the distinctive lncRNA identified in the recurrentNPCmay reveal a distinctive development
mechanism underlying tumor recurrence.
1. Introduction
Undifferentiated nasopharyngeal carcinoma (NPC) is preva-
lent in specific geographic localities including Southern
China and East Asia, Southeast Asia, Greenland (native),
Canada (Northwest Territories), and Alaska. Undifferenti-
ated NPC is characterized by its close association with the
virology of Epstein-Barr virus, a gamma-herpes DNA virus
that infectsmore than 90% of world’s population and is found
in nearly all undifferentiated NPC cells [1]. According to
the World Health Organization classification (WHO 2005),
NPC could be classified based on the cancer differentiation
status into type 1 keratinising squamous cell carcinoma and
type 2 nonkeratinising carcinoma (differentiated and undif-
ferentiated NPC). In endemic regions, the major histological
type is type 2 NPC [2]. Early diagnosis of NPC is difficult
as the cancer is developed from the epithelial lining around
the ostium of the Eustachian tube in the lateral wall of the
nasopharynx with close proximity to the skull [3]. Later
diagnosis will usually lead to unsatisfactory treatment results
and high incidence of local regional recurrence [4].
lncRNAs are non-protein-coding transcripts transcribed
by either RNA Pol I, RNA Pol II, or RNA Pol III. Dif-
ferent from the protein-coding genes, lncRNA has distinct
biological function in maintaining the cellular homeosta-
sis [5]. Prensner and Chinnaiyan summarized our current
knowledge on lncRNA in the pathogenesis and progression
of human malignancies [6]. At present, we know that long or
large intergenic ncRNAs, transcribed ultraconserved regions,
pseudogenes, enhancer RNAs, antisense RNAs, and long
stress-induced noncoding transcribes are involved in the
development and tumorigenesis of cancers. The existence of
these noncoding RNAs used to be regarded as transcriptional
byproducts with no significant functions. Over the past
decade, however, increasing evidence suggested that lncRNA
could function as epigenetic regulators, modulators of gene
expression, and protein degradationmachinery aswell as reg-
ulators of organelle biogenesis and subcellular trafficking [7].
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Hence, further understanding of the aberrant expression
pattern of lncRNA in cancers is essential.
Study on lnRNA deregulation in undifferentiated NPC
remains raw. Recently, with the use of candidate gene
approach, it was identified that HOX antisense intergenic
RNA (HOTAIR), one of the first described lncRNAs tran-
scribed in the HOXC locus at 12q13.13, was suggested to
play a part in NPC. HOTAIR was implicated in cancer
progression and metastasis. In primary NPC, high HOTAIR
expression was specific to the primary NPC and was absent
in the normal nasopharyngeal epithelia. HOTAIR expression
level was linked with the tumor size, nodal status, and
distantmetastasis. Further, patients with highHOTAIR levels
will have poor clinical outcome with tumor recurrence and
distant metastasis [8, 9].
High-throughput microarray was originally designed to
detect and quantify the protein-coding genes. However, it
is now noted that many of the probes on the microarray
also match with the sequence of lncRNA. By rematching
and reannotation of the existing microarray datasets, the
results obtained from the microarray experiments could be
used for lncRNA analysis concurrently. For example, with
the use of Affymetrix U133A and B microarrays, it has been
demonstrated that the microarray data can be reannotated
for lncRNA expression analysis [10]. Here, we explored the
differential lncRNA expression patterns in nasopharyngeal
carcinoma (NPC) based on the high-throughputNPCdataset
in the public domain using the functional reannotation
service provided by noncoding RNA Function ANnotation
server (ncFANs) [11]. The identified lncRNAs were validated
in both primary and recurrent NPC samples.
2. Materials and Methods
2.1. Dataset. Microarray data set GSE12452 containing 41
microarray data (http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE12452) was collected from Gene Expres-
sion Omnibus (GEO). The dataset contains 31 NPC and
10 normal nasopharyngeal tissue samples examined with
Human Genome U133 Plus 2.0 Array (HG-U133 Plus 2) from
Affymetrix [12]. The tissues were confirmed histologically
before the microarray experiment. Tumor tissue was defined
by the positive stain for both cytokeratins and EBV EBERs
using immunohistochemical staining. All the samples were
processed by laser-captured microdissection to enrich the
epithelial cells before total RNA extraction.
2.2. Patient Samples. Undifferentiated NPC tissue samples
were obtained from Department of Surgery, The Univer-
sity of Hong Kong, Queen Mary Hospital, Hong Kong.
Written consent of tissue donation for research purposes
was obtained from patients before tissue collection. The
protocol was approved by the IRB of the hospital (reference
number UW 10-142). Tissue samples were stored at liquid
nitrogen for transportation and stored at −70∘C before use. In
total, nasopharyngeal tissue samples were collected from 42
patients with primary NPC, 33 patients with recurrent NPC,
and 29 noncancer volunteers. The 42 patients with primary
NPC included 32 male and 10 female, with age ranging from
12 to 75 years.The 33 recurrentNPCpatients included 24male
and 9 female with age ranging from 29 to 75 years. The 29
healthy volunteers included 20 male and 9 female, with ages
ranging from 6 to 81 years.
2.3. Reannotation and Selection of Differential Expressed
lncRNA. The microarray data was preprocessed with the
preprocessing program and reannotated with the Affymetrix
CDF file from the web server of ncFANs (noncoding RNA
Function ANnotation server). The data was normalized by
MAS5.0 before lncRNAs annotation. Transcripts with length
<200 were excluded [11]. Differentially expressed lncRNAs
were selected using Student’s 𝑡-test using 𝑃 value below 0.05
as cutoff.
2.4. RNA Extraction and Real-Time Quantitative RT-PCRVal-
idation of the Microarray Results. Total RNA was extracted
with TRIZOL reagent (Invitrogen) following the manufact-
urer’s protocol. The cDNA product was generated using
cDNA conversion kit (Invitrogen). Primers were designed
with Primer3 provided by the Universal ProbeLibrary Assay
Design Center (http://www.roche-applied-science.com/).
The LNA-labelled probe was obtained from the Universal
ProbeLibrary (UPL). The lncRNA transcript levels were
quantified on LightCycler 480 (Roche Applied Science)
and normalized with the GAPDH levels by 2−ΔCt method.
All reactions were done in triplicate. Primer and probe
sequences were shown in Table 1.
2.5. Statistical Analysis. Statistical analysis was performed
with SPSS V16.0 (SPSS, Chicago, IL). The difference between
primary NPC and controls was calculated using the Mann-
Whitney 𝑈 test. The statistical difference between recur-
rent NPC and paired normal tissues was examined using
Wilcoxon Signed Rank test. All the tests were two-sided. 𝑃
value <0.05 was considered statistically significant.
3. Results
3.1. Functional Annotation of lncRNA with ncFANs. The
differentially expressed lncRNAs identified were listed
in Table 2. Five lncRNAs were found to be differentially
expressed in the nasopharyngeal carcinoma tissues in com-
parison with the normal nasopharyngeal epithelial tissues
in the microarray data. The lncRNAs identified were lnc-
C22orf32-1, lnc-TLR4-1, lnc-BCL2L11-3, lnc-AL355149.1-1,
and lnc-ZNF674-1.
3.2. lncRNA Validation on Primary NPC Tissues and Nor-
mal Nasopharyngeal Epithelia. To validate the identified
lncRNA, we performed real-time quantitative analysis on the
candidate lncRNA in our cohort. First, we examined the
fold changes in the primary nasopharyngeal carcinoma and
normal nasopharyngeal tissues (Figure 1). Among the 5 can-
didate lncRNAs, lnc-C22orf32-1, lncTLR4-1, lnc-AL355149.1-
1, and lnc-ZNF674-1 demonstrated significant expression
BioMed Research International 3
Table 1: Primer and probe sequences used in quantitative PCR.
Vega gene ID LNCipedia gene ID Forward primer (5󸀠-3󸀠) Reverse primer (5󸀠-3󸀠) UPL number∗
OTTHUMG00000153695 lnc-BCL2L11-3 agcagatgctgtgcctgata cctttctcgacccagaagc #67
OTTHUMG00000002490 lnc-AL355149.1-1 gaaaactaggcgtctgggaac caaacaatgggagcaagtcc #25
OTTHUMG00000150697 lnc-C22orf32-1 tgctcatcttctgccacagt agggcagtgatgaggaacc #38
OTTHUMG00000021416 lnc-ZNF674-1 agcacttggccctaaagaga aacatactggcccaaacagc #88
OTTHUMG00000020561 lnc-TLR4-1 ccacacaaatgggcaagaat gcaaaatcctgaaggttcaaa #6
∗Probe number in the universal probe library (UPL).
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Figure 1: Relative expression levels of lncRNAs in tissue samples frompatientswith primaryNPCandhealthy controls.The relative expression
levels were normalized to GAPDH by qPCR analysis. The difference between primary NPC and controls was calculated using the Mann-
Whitney 𝑈 test.
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Figure 2: Receiver operating characteristic (ROC) curve analysis of lncRNAs in tissue samples from patients with primary NPC and healthy
controls.
difference between the primary NPC and normal nasopha-
ryngeal tissues.
Of the 4 lncRNAs, the expression difference of lnc-
C22orf32-1 was highly significant (𝑃 = 0.001, Mann-Whitney
𝑈 test). High lnc-C22orf32-1 was found in the primary NPC
tissues in comparison with the normal controls (Figure 1). In
ROC analysis, the AUC value of lnc-C22orf32-1 was 0.734 in
differentiating NPC from the normal nasopharyngeal tissues
(Figure 2); lnc-AL355149.1-1 and lnc-ZNF674-1 were also
found to be overexpressed in the primary NPC tissues (𝑃 =
0.015 and 0.034, respectively, Mann-Whitney 𝑈 test). The 3
lncRNAs above are detectable in all the tissues examined. In
contrast, lnc-TLR4-1 was detectable in 21% (9/42) patients
with primary NPC and 66% (19/29) healthy controls. In
recurrent NPC, lnc-TLR4-1 was detectable in 27% (9/33)
tumor tissues and 15% (5/33) paired normal tissues. Low copy
number of lnc-TLR4-1 in tissue samples may account for
the low detection rate. The expression pattern of lnc-TLR4-
1 was not correlated with age or gender (data not shown).
Since lnc-TLR4-1 was only expressed in a subset of NPC and
normal nasopharyngeal tissues, it was not suitable for study
of differential expression.
Next, we compared the expression level of the 3 universal
expressed lncRNAs with the clinicopathological parameters
of the primary NPC patients (Table 3). High levels of lnc-
C22orf32-1 and lnc-AL355149.1-1 were significantly associated
with the male patients (Figure 3(b)). In addition, increased
expression of lnc-C22orf32-1 and lnc-ZNF674-1 was associ-
ated with advanced tumor stages (T2–4) in comparison with
the early stage (T1) NPC (Figure 3(a)).
3.3. Differential lncRNAs Expression in Recurrent NPC and the
Paired Normal Epithelia. We compared the lncRNA expres-
sion patterns with the paired normal tissues obtained from
6 BioMed Research International
Table 3: Association of lncRNA expression levels with the clinicopathological variables in primary undifferentiated NPC patients.
lnc-ZNF674-1 lnc-AL355149.1-1 lnc-C22orf32-1
𝑃 value
Gender Number
Male 32 0.108 0.028∗ 0.033∗
Female 10
Age
<49 19 0.733 0.970 0.810
>49 23
T stage
T1 11 0.030∗ 0.062 0.019∗
T2–4 31
Nodal status
Negative 7 0.895 0.692 0.692
Positive 35
∗
𝑃 value below 0.05 was considered statistically significant.
the same recurrent NPC patients (Figure 4). lnc-BCL2L11-3
was found to be upregulated in the recurrent NPC tissues
in comparison with the paired normal tissues (𝑃 = 0.002,
Wilcoxon Signed Rank test). For lnc-AL355149.1-1 and lnc-
ZNF674-1, high expression was found in primary NPC.
However, significant expression reduction was observed in
the recurrent NPC tissues (𝑃 = 0.022 and 0.002, respectively,
Wilcoxon Signed Rank test).
4. Discussion
The differential expression of lnc-AL355149.1-1, lnc-
C22orf32-1, and lnc-ZNF674-1 observed in NPC might be
attributed to epigenetic regulation including microRNA,
DNAmethylation, and histone modification. As predicted by
a bioinformatics tool MirTarget2 (http://mirdb.org/miRDB/
index.html), lnc-AL355149.1-1 is targeted by hsa-miR-939,
hsa-miR-4283, and hsa-miR-3191-5p; lnc-C22orf32-1 is tar-
geted by hsa-miR-4751; lnc-ZNF674-1 is targeted by hsa-
miR-1296, hsa-miR-1292, and hsa-miR-3179. In addition,
DNA methylation and histone modification may also
contribute to the aberrant expression of these lncRNAs. For
example, DNA methylation, H3K4 histone methylation,
and H3K9 histone methylation are found in lnc-
AL355149.1-1 gene in different human cell lines (lncRNome,
http://genome.igib.res.in/lncRNome/).
lncRNAs could exert biological functions by interacting
with RNA or protein molecules. An lncRNA, highly upreg-
ulated in liver cancer (HULC), could bind to miR-372, thus
modulating the expression of miR-372 at posttranscriptional
level [13]. lncRNA HOTAIR interacted with polycomb chro-
matin remodeling complex 2 (PRC2) by its 5󸀠 domain and
bind to LSD1/CoREST/REST complex via its 3󸀠 domain,
resulting in a specific histone methylation pattern [14]. To
explore the possible model by which these differentially
expressed lncRNAs exert their biological functions, we tried
to predict their binding capacity via database lncRNome.
The nucleotides 595–597 of lnc-ZNF674-1 are predicted to be
protein binding sites, indicating that itmay play a role inNPC
by interacting with specific proteins.
Primary NPC is highly sensitive to radiotherapy and
the use of concurrent chemoradiotherapy has significantly
improved the local control rates of NPC [15]. Nevertheless,
local recurrence still appears in approximately 10–30% of
patients after primary radiotherapy [16]. Since recurrent
NPC is possibly derived from those NPC cells that could
escape from radiotherapy, the recurrent NPC might exhibit
distinctive mRNA, miRNA, and protein expression patterns
in comparison with primary NPC. For instance, the expres-
sion levels of miR-98, TR-𝛼2 mRNA, multidrug resistance 1
(MDR-1) protein, and glutathione-S-transferase-𝜋 (GST-𝜋)
protein were different between recurrent NPC and primary
NPC [17, 18]. Likewise, in this study, we also observed a
diverse lncRNA expression pattern between recurrent NPC
and primary NPC. For example, the aberrant expression of
lnc-BCL2L11-3 was only observed in recurrent NPC but not
in primaryNPC, suggesting that lncRNAsmight play distinct
roles in the initiation and progression of recurrent NPC and
primary NPC.
According toGlobal Cancer Statistics [19], NPC is amale-
dominant disease with incidence rates usually 2 to 3 times
lower in females. In our cohort, the ratio between males
and females is about 3. Therefore, one of the limitations
of this study is the small sample size of females. Another
concern about our patient samples is the large age range.
To investigate whether the large age range would affect the
expression level of lncRNAs, we divided our patients into two
groups according to various cutoff values of age.There are no
significant differences in the expression of lncRNAs between
the two groups of patients divided by varied cutoff values of
age.
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Figure 3: Relative expression levels of lncRNAs in primary NPC patients with different T stage (a) and gender (b). The relative expression
levels were normalized to GAPDH by qPCR analysis. The difference was calculated using the Mann-Whitney 𝑈 test.
The differential lncRNA expression patterns could be
represented by the microarray probsets, which were orig-
inally intended to map the somatic gene expression level.
This approach has proven successful in identifying the altered
lncRNA expression in the nucleus accumbens of heroin
abusers. Michelhaugh SK reanalyzed the existing Affymetrix
microarray dataset and identified the 5 lncRNAs dysregulated
in the heroin abusers [10]. They curated existing RNA
databases including RNAdb and H-Invitational to generate
a list of lncRNA and later matched them with the probeset
on the Affymetrix U133A and U133B chips [10]. Using similar
approaches, we demonstrated that the differential lncRNA
expression data could possibly be retrieved from the existing
microarray dataset for use, to identify candidate lncRNA
which is implicated in the pathogenesis of NPC.
5. Conclusions
Our results demonstrated that it is feasible to identify the
differentially expressed lncRNA in the microarray dataset
by functional reannotation. The association of lncRNA with
gender and tumor size implicated that lncRNA possibly
plays a part in the pathogenesis of primary NPC. Further,
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Figure 4: Relative expression levels of lncRNAs in paired tumor and normal tissue samples from patients with recurrent NPC. The relative
expression levels were normalized toGAPDH by qPCR analysis.The difference between tumor and normal was calculated using theWilcoxon
Signed Rank test.
the distinctive lncRNA identified in the recurrent NPC
may reveal a distinctive development mechanism underlying
tumor recurrence. Further studies are warranted to explore
the pathological significance of lncRNA in the development
of NPC.
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